Department of Urology, Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325035, PR China; Engineering Research Center of Clinical Functional Materials and Diagnosis & Treatment Devices of Zhejiang Province, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang Province, 325011, PR China.
Engineering Research Center of Clinical Functional Materials and Diagnosis & Treatment Devices of Zhejiang Province, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang Province, 325011, PR China; School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian Province, 361102, PR China.
Biochem Biophys Res Commun. 2021 Jun 18;558:107-113. doi: 10.1016/j.bbrc.2021.04.040. Epub 2021 Apr 24.
MicroRNAs play an irreplaceable role in gene expression regulation. Upregulation of several miRNAs increases the risk of invasion and metastasis of breast cancer cells. An oncogenic miRNA, miR-21, is highly expressed in triple-negative breast cancer (TNBC) and is associated with tumor proliferation, invasion, carcinogenesis, prognosis, and therapeutic resistance. However, targeted delivery of therapeutic anti-miRNAs into cancer cells remains challenging, especially for TNBC. In this study, we report the application of an RNA nanotechnology-based platform for the targeted delivery of anti-miR-21 by epidermal growth factor receptor (EGFR) aptamer in vitro to TNBC and chemical-resistant breast cancer cells. RNA nanoparticles reduced cell viability and sensitized breast cancer cells to doxorubicin (DOX) treatment in vitro. Inhibition of miR-21 by RNA nanoparticles suppressed TNBC cell invasion, migration, and colony formation. The results indicate the potential application of nanotechnology-based delivery platforms in clinical anti-cancer therapeutics.
微小 RNA 在基因表达调控中发挥着不可替代的作用。几种 miRNA 的上调增加了乳腺癌细胞侵袭和转移的风险。致癌 miRNA，miR-21，在三阴性乳腺癌（TNBC）中高表达，与肿瘤增殖、侵袭、癌变、预后和治疗耐药性有关。然而，将治疗性抗 miRNA 靶向递送到癌细胞中仍然具有挑战性，特别是对于 TNBC。在这项研究中，我们报告了一种基于 RNA 纳米技术的平台在体外靶向递送 EGFR 适体抗 miR-21 的应用，用于 TNBC 和化学抗性乳腺癌细胞。RNA 纳米颗粒降低了细胞活力，并使乳腺癌细胞对阿霉素（DOX）治疗敏感。RNA 纳米颗粒抑制 miR-21 抑制了 TNBC 细胞的侵袭、迁移和集落形成。结果表明，基于纳米技术的递药平台在临床抗癌治疗中有应用潜力。
